Eli Lilly's oral weight-loss drug shows major fat loss across stages of menopause in trials
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions

